Loading...
•
Mar 31, 2023
Ventyx Biosciences Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Ventyx Biosciences reported a net loss of $38.9 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $376.9 million as of March 31, 2023, which is expected to fund operations into 2025. Five Phase 2 clinical trials are ongoing.
Phase 2 trials of VTX958 are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023.
The Phase 2 trial of VTX002 in ulcerative colitis is progressing, with topline data expected in H2 2023.
Cash, cash equivalents and marketable securities were $376.9 million as of March 31, 2023, expected to fund planned operations into 2025.
A Phase 1 trial of CNS-penetrant NRLP3 inhibitor VTX3232 is expected to be initiated this quarter.
Forward Guidance
Ventyx anticipates key milestones in its clinical programs and expects current resources to fund operations into 2025.
Positive Outlook
- Anticipated timing of commencement, enrollment and completion of clinical trials for Ventyx’s product candidates
- Anticipated timing for releasing topline data for clinical trials of Ventyx’s product candidates
- Anticipated timing for providing an update on VTX958 extended release tablet development
- Anticipated timing for nominating a lead candidate for the IL-4Rα discovery program
- Expected timeframe for funding Ventyx’s operating plan with current cash, cash equivalents and marketable securities
Challenges Ahead
- Potential delays in the commencement, enrollment and completion of clinical trials
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
- Disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...